List view / Grid view
14 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Zoptrex, a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients…
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial...
5 May 2016 | By Victoria White, Digital Content Producer
Ergomed is acquiring 100% of the issued share capital of Haemostatix for an initial consideration of £8.0 million...
